The first FDA-approved systemic therapy may be beneficial to patients with low-grade astrocytoma or oligodendroglioma with IDH1 or 2 mutations. The recent Food and Drug Administration (FDA) approval ...

Eflornithine plus Gleostine improved OS and PFS in recurrent grade 3 IDH-mutated astrocytoma compared to Gleostine alone. The STELLAR study reclassified patients using updated WHO 2021 criteria, ...

A research team has discovered a previously overlooked subtype of brain tumor termed IME IDH-mutant astrocytoma. Contrary to typical medical expectations, this subtype exhibits strong immune activity, ...

IDH-mutant, grade 3 astrocytoma is a serious condition, and many of these tumors return even after aggressive, upfront treatment. By adding a newer, targeted therapy aimed at the underlying IDH ...

Pilocytic astrocytoma is a generally benign glial neoplasm classified as WHO grade I, most frequently encountered in children and young adults. These tumours exhibit a biphasic histological pattern, ...

The following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted ...

This can be used to predict patient prognosis and drive the development of novel therapies." Until a cure is found for the most aggressive astrocytomas, the priority for oncologists is to detect their ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved vorasidenib for certain patients with astrocytoma or oligodendroglioma. The indication applies ...

Irene Rodríguez-Hernández; Marta Vázquez-Cedeira; Angel Santos-Briz; Juan L García; Isabel F Fernández; Juan A Gómez-Moreta; Javier Martin-Vallejo; Rogelio González-Sarmiento; Pedro A Lazo In summary, ...

Huntsman Cancer Institute at the University of Utah (the U) participated in a clinical trial that found that a new combination treatment plan helped people with recurring grade 3 astrocytoma, an ...